B. Riley Wealth Advisors’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-653
Closed -$318K 1117
2025
Q4
$318K Sell
653
-31
-5% -$14.4K 0.01% 690
2025
Q3
$287K Sell
684
-62
-8% -$20.9K 0.01% 742
2025
Q2
$214K Sell
746
-137
-16% -$40.9K 0.01% 868
2025
Q1
$272K Sell
883
-67
-7% -$23K 0.01% 1016
2024
Q4
$335K Sell
950
-50
-5% -$18.4K 0.01% 831
2024
Q3
$357K Sell
1,000
-67
-6% -$22.6K 0.01% 874
2024
Q2
$340K Buy
1,067
+99
+10% +$26.2K 0.01% 968
2024
Q1
$219K Buy
+968
New +$218K 0.01% 1226
2023
Q4
Sell
-968
Closed -$219K 1506
2023
Q3
$219K Buy
+968
New +$223K 0.01% 1226
2018
Q2
Sell
-1,882
Closed -$212K 734
2018
Q1
$212K Sell
1,882
-70
-4% -$8.89K 0.03% 568
2017
Q4
$289K Sell
1,952
-205
-10% -$26.1K 0.04% 464
2017
Q3
$253K Buy
+2,157
New +$275K 0.04% 428
2015
Q1
Sell
-190
Closed -$25K 1919
2014
Q4
$25K Buy
+190
New +$24.5K ﹤0.01% 2451
2014
Q3
Sell
-276
Closed -$24.4K 1829
2014
Q2
$24.4K Buy
+276
New +$26.5K 0.01% 1381
2013
Q4
Sell
-2,270
Closed -$179K 723
2013
Q3
$179K Sell
2,270
-540
-19% -$39.5K 0.06% 372
2013
Q2
$185K Buy
+2,810
New +$181K 0.06% 357

Other funds holding UTHR

B. Riley Wealth Advisors's UTHR Position: Q1 2026 in Review

B. Riley Wealth Advisors sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 653 shares — an estimated $318K sold.

B. Riley Wealth Advisors first reported a position in UTHR in Q2 2013 and held it in 16 quarters. The position peaked at $357K in Q3 2024. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • B. Riley Wealth Advisors reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 653 United Therapeutics shares in Q1 2026, an estimated $318K.
  • B. Riley Wealth Advisors first reported a position in United Therapeutics in Q2 2013 and held it in 16 quarters.
  • B. Riley Wealth Advisors's United Therapeutics position peaked at $357K in Q3 2024.
  • 854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.